Revolution’s lead RAS blocker heads into Phase 3 in frontline pancreatic...
Revolution Medicines said it will begin a late-stage test of its lead asset as a first-line treatment for a form of pancreatic cancer, after a Phase 1 study in this setting yielded promising data. ...
View ArticleSEC files charges against former FibroGen CMO for manipulating clinical trial...
FibroGen is facing another development in a yearslong saga over manipulated data for its anemia drug. The Securities and Exchange Commission is bringing charges against the company’s former chief...
View ArticleSophont raises $9.2M to build multimodal foundation models
Sophont wants to build a foundation model that can analyze all sorts of specialized medical data and make it open-source. The idea is to start by training separate models on specific types of medical...
View ArticleA conversation with Lasker Award winner Michael Welsh on life-saving cystic...
A trio of scientists whose work has helped turn cystic fibrosis from a lethal disease to a treatable condition won the Lasker-DeBakey Clinical Medical Research Award on Thursday. Often referred to as...
View ArticleThe UK is falling behind on life science investments, trade group warns
The Association of the British Pharmaceutical Industry is warning that the UK is a "contagion risk” for global investors as pharmaceutical companies move R&D investments to other countries. The ABPI’s
View ArticleMaze’s SLC6A19 inhibitor moves to Phase 2; GenFleet to go public in Hong Kong
💰 Maze Therapeutics’ stock soars on Phase 1 data, $150M raise: The company said the healthy volunteer data for its experimental treatment for phenylketonuria and chronic kidney disease support the plan...
View ArticleIntercept pulls liver disease drug from market as FDA puts clinical trials on...
Intercept Pharmaceuticals said it is withdrawing Ocaliva from the US market, following a request from the FDA. The FDA also put a hold on all clinical trials involving Ocaliva, otherwise known as...
View ArticleLGC opens $72M chemical plant; Recipharm partners with NeuroSense
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. LGC has opened its new $72 million facility in Ontario, Canada, the ...
View ArticleAvidity shares fall after $500M offering, dimming hopes of a Novartis buyout
Is Avidity Biosciences signaling that it won’t be getting acquired any time soon? The company announced Wednesday afternoon that it's aiming to raise $500 million in a public offering on the ...
View ArticleRFK Jr.'s 'historic changes' to drug ads would trigger range of ripple effects
For years, the end of every pharmaceutical ad has been a well-worn convention: After smiling patients are done walking down the beach, or singing while walking down the beach, a voice reads a summary...
View ArticlePrasad regains chief medical and scientific officer roles at FDA
Vinay Prasad, who briefly left his role and then returned as head of the FDA’s Center for Biologics Evaluation and Research, has regained two additional titles of chief medical and scientific officer....
View ArticleAlternative health plan startup XO Health raises $52.2M
Alternative health plan startup XO Health has raised $52.2 million, Endpoints News has learned. CEO Swati Mathai confirmed to Endpoints that the money, initially disclosed in a securities filing,...
View ArticleNovartis loses IRA appeals case
A federal appeals court on Thursday rejected Novartis’ challenge against Medicare drug price negotiations, a week after tossing similar cases brought by Johnson & Johnson and Bristol Myers Squibb....
View ArticleAbbVie staves off Rinvoq generics until 2037
AbbVie said it has fended off US generic competition for one of its top-selling drugs until 2037. The company announced in a securities filing on Thursday that it has settled legal ...
View ArticleOusted FDA official joins Lilly; Novo names global research head as layoffs...
A former top cell and gene therapy regulator at the FDA is joining Eli Lilly in a policy role for the same therapeutic area. Rachael Anatol
View ArticleKalVista reports strong sales in early launch of hereditary angioedema drug
KalVista Pharmaceuticals’ treatment for a rare disease that causes swelling attacks is enjoying a stronger-than-expected launch, but Wall Street analysts said continued momentum could depend on how...
View ArticlePfizer has a VEGF bispecific strategy. And it’s very different than Summit’s
As Wall Street continues to digest this week’s disappointing results for Summit Therapeutics’ PD-1xVEGF bispecific cancer drug, one competitor is primed to take advantage. Summit’s stock {$SMMT} closed...
View ArticleA new biotech fund in the Middle East; Xspray preps for FDA decision on Dasynoc
Plus, news about Nacuity, Dianthus Therapeutics and Avidity Biosciences: 🇸🇦 Middle East biotech fund emerges: The Sarat Ventures Y Innovations Biotech Fund unveiled this week to invest in about $50...
View ArticleLilly’s UK Gateway Labs plans uncertain in new blow to region's biopharma...
Eli Lilly said that it's “not yet in a position to finalize” plans to bring its Gateway Labs to the UK, as it is “awaiting more clarity” on the state of the country’s life sciences ...
View ArticleLilly loses bid to overturn $183.7M judgment in Medicaid rebate fight
Eli Lilly must pay $183.7 million in damages in a case alleging it underpaid drug rebates to Medicaid, a federal appeals court ruled. The US Court of Appeals for the Seventh Circuit on Thursday ...
View ArticleTop drug regulator pushes back on report that FDA wants to 'abandon' some...
The FDA's top drug regulator denied a report that said he might "abandon" certain advisory committee meetings that often review controversial drug candidates before potential approval. Center for Drug...
View ArticleAstraZeneca halts another UK investment, following Merck and Lilly moves
AstraZeneca is halting a $271 million investment in its Cambridge research site, the third pharma company this week to reconsider its commitment to expand in the UK. “We constantly reassess the...
View ArticleNovo Nordisk’s ongoing challenges; Summit’s Western data disappoint; Eli...
Welcome back to another edition of Endpoints Weekly! It’s conference season here in New York, and our reporters have been in and around the city chatting with all sorts of folks. Thankfully, the...
View ArticleLila Sciences is near a $300M+ fundraise to back autonomous science: source
The AI startup Lila Sciences is closing in on a Series A round to raise $300 million or more, Endpoints News has exclusively learned, funding its vision of building “scientific superintelligence.” The...
View Article